Rare cancers account for ~25–30% of all cancer diagnoses and 25% of cancer deaths, representing a substantial burden of disease. However, basic science research, clinical trials and approval of new therapies for rare cancers are lacking. This translates into a worse prognosis for patients with a rare cancer than for those with common cancers. With the number of rare cancers increasing, finding more appropriate solutions for diagnosing, managing and studying rare cancers is essential.
Matthieu Foll was invited speaker in the 25th European Congress of Endocrinology (ECE 2023) in ...
Lynnette Fernandez-Cuesta and Matthieu Foll will be presenting at the upcoming EMBL Cancer Genomics Conference ...
As every year, a unique opportunity to learn about the advances made in the field ...
Rare Cancer Genomics
NETRF 2022
RCG Initiative 2020